Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HAE Stock Forecast 2025-2026
$70.06
Current Price
$3.32B
Market Cap
Buy 8
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to HAE Price Targets
+54.2%
To High Target of $108.00
+32.0%
To Median Target of $92.50
-2.9%
To Low Target of $68.00
HAE Price Momentum
-1.8%
1 Week Change
+1.0%
1 Month Change
-18.0%
1 Year Change
-10.3%
Year-to-Date Change
-26.2%
From 52W High of $94.99
+26.7%
From 52W Low of $55.30
📊 TOP ANALYST CALLS
Did HAE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Haemonetics is one of their latest high-conviction picks.
Latest HAE Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, HAE has a bullish consensus with a median price target of $92.50 (ranging from $68.00 to $108.00). Currently trading at $70.06, the median forecast implies a 32.0% upside. This outlook is supported by 8 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Mike Matson at Needham, projecting a 54.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HAE Analyst Ratings
8
Buy
1
Hold
1
Sell
HAE Price Target Range
Low
$68.00
Average
$92.50
High
$108.00
Current: $70.06
Latest HAE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HAE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 20, 2025 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $100.00 |
| May 9, 2025 | Raymond James | Andrew Cooper | Strong Buy | Reiterates | $105.00 |
| May 8, 2025 | Needham | Mike Matson | Buy | Maintains | $84.00 |
| Mar 18, 2025 | Needham | Mike Matson | Buy | Maintains | $104.00 |
| Feb 7, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Feb 7, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $100.00 |
| Feb 7, 2025 | Raymond James | Andrew Cooper | Strong Buy | Reiterates | $115.00 |
| Feb 7, 2025 | Needham | Mike Matson | Buy | Maintains | $108.00 |
| Dec 6, 2024 | JP Morgan | Rohin Patel | Overweight | Initiates | $116.00 |
| Dec 4, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Dec 3, 2024 | Needham | Mike Matson | Buy | Reiterates | $112.00 |
| Nov 15, 2024 | Needham | Mike Matson | Buy | Reiterates | $112.00 |
| Nov 8, 2024 | Raymond James | Andrew Cooper | Strong Buy | Upgrade | $120.00 |
| Nov 8, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Sep 23, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $108.00 |
| Sep 13, 2024 | CL King | Kristen Stewart | Buy | Initiates | $116.00 |
| Sep 11, 2024 | B of A Securities | Craig Bijou | Neutral | Initiates | $85.00 |
| Sep 10, 2024 | BTIG | Marie Thibault | Buy | Initiates | $112.00 |
| Aug 22, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $85.00 |
| Aug 13, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $125.00 |
Haemonetics Corporation (HAE) Competitors
The following stocks are similar to Haemonetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Haemonetics Corporation (HAE) Financial Data
Haemonetics Corporation has a market capitalization of $3.32B with a P/E ratio of 20.8x. The company generates $1.36B in trailing twelve-month revenue with a 12.3% profit margin.
Revenue growth is -3.7% quarter-over-quarter, while maintaining an operating margin of +17.2% and return on equity of +18.8%.
Valuation Metrics
Market Cap
$3.32B
Enterprise Value
$4.29B
P/E Ratio
20.8x
PEG Ratio
12.9x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
-3.7%
Gross Margin
+58.4%
Operating Margin
+17.2%
Net Margin
+12.3%
EPS Growth
+184.7%
Financial Health
Cash/Price Ratio
+9.2%
Current Ratio
1.6x
Debt/Equity
156.3x
ROE
+18.8%
ROA
+6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Haemonetics Corporation (HAE) Business Model
About Haemonetics Corporation
What They Do
Provides innovative blood management solutions.
Business Model
Haemonetics Corporation generates revenue by offering a range of devices and services tailored for blood collection, processing, and management. Its business model focuses on supplying hospitals and blood centers with advanced technology and software solutions that enhance operational efficiency and ensure the safety of blood supply.
Additional Information
Headquartered in Boston, Massachusetts, Haemonetics is dedicated to improving patient care and blood donor experiences. The company plays a critical role in transfusion medicine, supporting healthcare providers globally with its comprehensive product offerings.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,657
CEO
Mr. Christopher A. Simon
Country
United States
IPO Year
1991
Website
www.haemonetics.comHaemonetics Corporation (HAE) Latest News & Analysis
Latest News
Quick Summary
Haemonetics Corporation's CEO Chris Simon will speak at the Goldman Sachs Healthcare Conference on June 9, 2025, at 8:40 a.m. ET. A live webcast will be available on their Investor Relations site.
Why It Matters
Haemonetics' CEO will address investors at a key healthcare conference, potentially influencing stock perception and providing insights into company strategy and performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Haemonetics reported strong fourth-quarter fiscal 2025 results, showing significant earnings growth and margin expansion due to its long-term strategic plan.
Why It Matters
Haemonetics' strong earnings growth and margin expansion indicate effective strategic execution, potentially boosting investor confidence and driving stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Haemonetics Corporation (NYSE:HAE) will hold its Q4 2025 Earnings Conference Call on May 8, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
Why It Matters
The earnings call provides insights into Haemonetics' financial performance and strategic direction, influencing stock price and investor sentiment. Key analysts' questions may reveal market expectations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Haemonetics (HAE) reported its quarterly results for March 2025, with key metrics available for comparison against Wall Street estimates and the previous year's performance.
Why It Matters
Comparing Haemonetics' performance to Wall Street estimates and previous year results helps gauge financial health, growth trends, and market expectations, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
1 month ago
Quick Summary
Haemonetics Corporation (NYSE: HAE) has released its Q4 and FY 2025 financial results, available on its Investor Relations website. A conference call is scheduled for May 8, 2025, at 8:00 a.m. EST.
Why It Matters
Haemonetics' financial results and upcoming conference call provide insights into its performance, affecting stock valuation and investor sentiment. Key metrics may influence trading decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors should review Wall Street's estimates and key metrics for Haemonetics (HAE) to assess its performance for the quarter ended March 2025.
Why It Matters
Key metrics projections for Haemonetics provide insights into its financial health and operational performance, influencing investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About HAE Stock
What is Haemonetics Corporation's (HAE) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Haemonetics Corporation (HAE) has a median price target of $92.50. The highest price target is $108.00 and the lowest is $68.00.
Is HAE stock a good investment in 2025?
According to current analyst ratings, HAE has 8 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $70.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HAE stock?
Wall Street analysts predict HAE stock could reach $92.50 in the next 12 months. This represents a 32.0% increase from the current price of $70.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Haemonetics Corporation's business model?
Haemonetics Corporation generates revenue by offering a range of devices and services tailored for blood collection, processing, and management. Its business model focuses on supplying hospitals and blood centers with advanced technology and software solutions that enhance operational efficiency and ensure the safety of blood supply.
What is the highest forecasted price for HAE Haemonetics Corporation?
The highest price target for HAE is $108.00 from Mike Matson at Needham, which represents a 54.2% increase from the current price of $70.06.
What is the lowest forecasted price for HAE Haemonetics Corporation?
The lowest price target for HAE is $68.00 from at , which represents a -2.9% decrease from the current price of $70.06.
What is the overall HAE consensus from analysts for Haemonetics Corporation?
The overall analyst consensus for HAE is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $92.50.
How accurate are HAE stock price projections?
Stock price projections, including those for Haemonetics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 3:21 AM UTC